The accelerated NOVA-2 readout to H1 2027 and strong cash runway through Q2 2029 reduce binary risk and support pipeline expansion. Monitor enrollment updates and any pre-NDA meeting announcements in H2 2027 as key catalysts.
Price Chart
Executive Summary
LB Pharmaceuticals reported Q2 2026 net loss of $51.6M ($1.71/share) vs $4.9M a year ago, reflecting heavy R&D investment in Phase 3 NOVA-2 and Phase 2 ILLUMINATE-1 trials. The key catalyst is the accelerated NOVA-2 topline readout to H1 2027 (from H2 2027) and a $150M July private placement extending cash runway beyond Q2 2029, supporting pipeline expansion into new indications.
Key Financial Metrics
Key Facts
- Q2 2026 net loss of $51.6M ($1.71/share) vs $4.9M ($13.58/share) in Q2 2025
- Phase 3 NOVA-2 topline data accelerated to H1 2027, ahead of prior guidance
- Pre-NDA meeting with FDA expected in H2 2027
- Cash, cash equivalents, and marketable securities of $327.8M as of June 30, 2026
- July 2026 private placement of $150.0M extends cash runway beyond Q2 2029
- Phase 2 ILLUMINATE-1 (bipolar depression) topline data expected Q1 2028
- Phase 2 trial in adjunctive MDD initiation expected early 2027, data H1 2029
- R&D expenses $44.1M in Q2 2026 vs $2.4M in Q2 2025, driven by Phase 3 trial costs
Financial Impact
Net loss of $51.6M in Q2 2026 vs $4.9M in Q2 2025; cash position $327.8M plus $150M private placement provides runway beyond Q2 2029
Risk Factors
- Phase 3 NOVA-2 trial failure or mixed results
- Regulatory delays or FDA rejection of pre-NDA package
- Dilution risk from future capital raises despite current cash runway
- Competition from existing antipsychotics and other pipeline candidates
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3342636 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | SC 13G/A | $34.79 | awaiting T+60 | — | $39.34 (+13.08%) |
Oct 6, 2026 20d ago | EFFECT | $34.26 | awaiting T+60 | — | $39.34 (−14.83%) |
Sep 15, 2026 5w ago | 8-K | $43.04 | awaiting T+60 | — | $39.34 (−8.60%) |
Sep 3, 2026 7w ago | 8-K | $47.52 | awaiting T+60 | — | $39.34 (−17.21%) |
Aug 11, 2026 10w ago | 8-K | $45.33 | awaiting T+60 | — | $39.34 (−13.21%) |
Aug 11, 2026 10w ago | Press Release | $45.33 | awaiting T+60 | — | $39.34 (−13.21%) |
Jul 29, 2026 12w ago | 8-K | $39.00 $39.42 | ▲ +1.08% | ▼ −3.65% | $39.34 (+0.87%) |
Jul 22, 2026 13w ago | 8-K | $35.84 $36.69 | ▲ +2.37% | ▼ −0.89% | $39.34 (+9.77%) |
Jul 22, 2026 13w ago | Press Release | $35.84 $36.69 | ▲ +2.37% | ▼ −0.89% | $39.34 (+9.77%) |
Jun 10, 2026 19w ago | 8-K | $28.54 | awaiting T+60 | — | $39.34 (+37.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers